Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 30 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.

Trial Profile

An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 30 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brexpiprazole (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 20 Sep 2016 Results from this and other two open label studies ( profiles 240013 and 239811), presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.
    • 01 Sep 2015 Primary endpoint (MADRS Total Score change from baseline to Week 12 [ Time Frame: Week 12 ] has been met as per results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
    • 01 Sep 2015 Results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top